Financings Of The Fortnight: Shield Therapeutics Reveals Switzerland As Series A Hot Spot
This article was originally published in The Pink Sheet Daily
Executive Summary
Plus details on recent financings by Cyterix Pharmaceuticals, Intrexon and Constellation Pharmaceuticals.
You may also be interested in...
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. launched in August 2011 as a spin out of Vantia Therapeutics. KalVista acquired a portfolio of small-molecule plasma kallikrein inhibitors from Vantia's preclinical store. The compounds will be developed to treat diabetic macular edema, a condition that threatens the vision of up to a quarter of the world's 285 million diabetes sufferers.
Shrinking Funding Rounds For European Biotechs Are No Surprise, But Series A Rounds Look Healthy, If Few
Nearly half (48%) of the 27 fundraisings by private European biotech companies so far this year have been for sums totaling $10 million or less, according to Elsevier's "Strategic Transactions" database. That's a significant increase over the same period in 2010, when less than 30% of financings were sub-$10 million.
Shrinking Funding Rounds For European Biotechs Are No Surprise, But Series A Rounds Look Healthy, If Few
Nearly half (48%) of the 27 fundraisings by private European biotech companies so far this year have been for sums totaling $10 million or less, according to Elsevier's "Strategic Transactions" database. That's a significant increase over the same period in 2010, when less than 30% of financings were sub-$10 million.